2018 Annual Meeting | C116 - Cerebrovascular Disease I: Prevention

Date Tuesday 04/24/18

Time 01:00 PM - 03:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Larry B. Goldstein, MD, FAHA, FAAN

Topic(s)

Learning Objectives Participants should be able to discuss recent changes in stroke epidemiology, recommend appropriate lifestyle changes for stroke prevention, understand the indications and choice of platelet antiaggregants, and discuss risks and benefits of closure of a patent foramen ovale in patients with cryptogenic stroke.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Interpersonal and Communication Skills, Practice-based Learning and Improvement

Program Tracks Advanced Practice Provider, Neurohospitalist

Recommended Audience Trainee, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider

Teaching Styles Didactic, Interactive

Event Timeline
01:00 PM - 01:25 PM	Speaker	Changing Epidemiology and Importance of Lifestyle Larry B. Goldstein, MD, FAHA, FAAN
01:25 PM - 01:30 PM	Q&A	Questions and Answers Larry B. Goldstein, MD, FAHA, FAAN
01:30 PM - 02:05 PM	Speaker	Platelet Antiaggregants for Stroke Prevention Larry B. Goldstein, MD, FAHA, FAAN
02:05 PM - 02:10 PM	Q&A	Questions and Answers Larry B. Goldstein, MD, FAHA, FAAN
02:10 PM - 02:45 PM	Speaker	Patent Foramen Ovale in the Setting of Cryptogenic Stroke Steven R. Messe, MD, FAHA, FAAN
02:45 PM - 02:50 PM	Q&A	Questions and Answers Steven R. Messe, MD, FAHA, FAAN
02:50 PM - 03:00 PM	Closing Remarks	Closing Remarks

Faculty Disclosures
Larry B. Goldstein, MD, FAHA, FAAN	The institution of Dr. Goldstein has received research support from NIH. The institution of Dr. Goldstein has received research support from NIH. The institution of Dr. Goldstein has received research support from NIH. The institution of Dr. Goldstein has received research support from NIH. The institution of Dr. Goldstein has received research support from NIH. The institution of Dr. Goldstein has received research support from Janssen. Dr. Goldstein has received publishing royalties from a publication relating to health care.
Steven R. Messe, MD, FAHA, FAAN	Dr. Messe has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novo Nordisk. Dr. Messe has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Terumo. Dr. Messe has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for WL Gore. The institution of Dr. Messe has received research support from WL Gore. The institution of Dr. Messe has received research support from Mallinkrodt. The institution of Dr. Messe has received research support from Biogen. Dr. Messe has received intellectual property interests from a discovery or technology relating to health care. Dr. Messe has received publishing royalties from a publication relating to health care. Dr. Messe has received personal compensation in the range of $500-$4,999 for serving as a Clinical Event Committee for the CONFORMAL left atrial appendage occlusion trial with Yale Cardiovascular Research Group.

��ɫ��

��ɫ��